Skip to main content
. Author manuscript; available in PMC: 2015 Mar 20.
Published in final edited form as: Vaccine. 2010 May 26;28(0 2):B25–B31. doi: 10.1016/j.vaccine.2009.10.131

Table 1.

Prechallenge immune responses in rhesus macaques.

T cell reactivity1 nAb titers2
SIV Gag HIV Tat HIV1084i gp160
Ab binding titers		 HIV1084i SHIV-1157ip
Group 1 (protein only) RLu-9 4,500 310 3.1 × 105 20 130
RNu-9 370 70 3.1 × 104 <10 <10
RVu-9 20 180 6.2 × 105 <10 15
RSr-9 4,400 1,560 6.2 × 105 <10 160
RAt-9 3,790 40 6.2 × 104 <10 130
Group 2 (DNA prime/protein boost) RHy-9 7,320 3,600 3.1 × 105 <10 50
RIy-9 270 140 6.2 × 105 <10 20
RJy-9 130 20 3.1 × 104 <10 140
RRz-9 7,130 3,100 3.1 × 104 <10 640
RBa-10 370 450 6.2 × 104 <10 120
Group 3 (control) RWq-9 0 0 <103 <10 <10
RAr-9 0 0 <103 <10 <10
RDr-9 40 0 <103 <10 <10
RPr-9 20 0 <103 <10 <10
ROa-10 0 0 <103 <10 <10

PBMC and sera of individual animals were tested 2 weeks after the final protein inoculations (day of SHIV-1157ip challenge).

1

T-cell responses in PBMC to peptide pools of the indicated viral antigen were determined by IFN-γ ELISPOT analysis and given as SFU/106 PBMC. Responses to each of three SIV Gag peptide pools have been summed.

2

Serum neutralizing antibody titers to HIV1084i and SHIV-1157ip were measured using the TZM-bl-based reporter assay and show the reciprocal dilution of sera giving 50% neutralization. adapted from Rasmussen et al.[13]